Brief: First Wave Biopharma Announces First Patient Dosed In Phase 2 Trial Of Enhanced Adrulipase Formulation
09/03/2023 12:35
March 9 (Reuters) - First Wave BioPharma Inc FWBI.O :
* FIRST WAVE BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN
PHASE 2
SPAN CLINICAL TRIAL OF ENHANCED ADRULIPASE FORMULATION
* FIRST WAVE BIOPHARMA INC - TOPLINE RESULTS FROM STUDY ARE
ANTICIPATED BY MID-2023
Source text for Eikon: ID:nGNX1gqjZj
Further company coverage: FWBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GridAI Technologies
See all newsBrief: Gridai Technologies Corp - Enters $2.54 Million Private Placement Of Shares And Warrants - SEC Filing
Brief: IBN Announces Latest Episode Of The Techmediawire Podcast Featuring Marshall Chapin, CEO Of Grid Ai Corp.
Brief: Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately - SEC Filing
Brief: Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock
Brief: Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement